Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK1 | Q9NYA1 | 4/20 | 0.38 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.38 |
| ▸ | AGL | P35573 | 1/20 | 0.34 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.34 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.34 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.34 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | PPM1B | O75688 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL116295 | 1.00 | SPHK1 (0.38) | SPHK1SLC1A2AGLCHRNB2CHRNA4 | |
| SCHEMBL203744 | 1.00 | SPHK1 (0.38) | SPHK1SLC1A2AGLCHRNB2CHRNA4 | |
| SCHEMBL6394380 | 1.00 | SPHK1 (0.38) | SPHK1SLC1A2AGLCHRNB2CHRNA4 | |
| SCHEMBL201157 | 1.00 | SPHK1 (0.38) | SPHK1SLC1A2AGLCHRNB2CHRNA4 | |
| SCHEMBL178593 | 1.00 | SPHK1 (0.38) | SPHK1SLC1A2AGLCHRNB2CHRNA4 | |
| SCHEMBL201158 | 1.00 | SPHK1 (0.38) | SPHK1SLC1A2AGLCHRNB2CHRNA4 | |
| Hydrochloric Acid SCHEMBL25381059 | 0.98 | SPHK1 (0.38) | SPHK1SLC1A2AGLCHRNB2CHRNA4 | |
| Hydrochloric Acid SCHEMBL201379 | 0.98 | SPHK1 (0.38) | SPHK1SLC1A2AGLCHRNB2CHRNA4 | |
| Hydrochloric Acid SCHEMBL1877388 | 0.98 | SPHK1 (0.38) | SPHK1SLC1A2AGLCHRNB2CHRNA4 | |
| Hydrochloric Acid SCHEMBL143428 | 0.98 | SPHK1 (0.38) | SPHK1SLC1A2AGLCHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11873291-B2 | Quinoline cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-11873291-B2 | Quinoline cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-20230339969-A1 | SUBSTITUTED MACROCYCLIC COMPOUNDS AND RELATED METHODS OF TREATMENT | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2023-10-26 | — | — | US | disclosed |
| US-20230339969-A1 | SUBSTITUTED MACROCYCLIC COMPOUNDS AND RELATED METHODS OF TREATMENT | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2023-10-26 | — | — | US | disclosed |
| US-11542276-B2 | Substituted macrocyclic compounds and related methods of treatment | ALKERMES, INC. (US) | 2023-01-03 | — | — | US | disclosed |
| US-20220194958-A1 | Substituted Macrocyclic Compounds and Related Methods of Treatment | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2022-06-23 | — | — | US | disclosed |
| WO-2021108628-A1 | SUBSTITUTED MACROCYCLIC COMPOUNDS AND RELATED METHODS OF TREATMENT | ALKERMES, INC. (US) | 2021-06-03 | — | — | WO | disclosed |
| US-20210155636-A1 | Substituted Macrocyclic Compounds and Related Methods of Treatment | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2021-05-27 | — | — | US | disclosed |
| EP-1506178-A4 | BICYCLIC MODULATORS OF ANDROGEN RECEPTOR FUNCTION | BRISTOL MYERS SQUIBB CO (US) | 2006-05-24 | — | — | EP | disclosed |
| EP-1506178-A2 | BICYCLIC MODULATORS OF ANDROGEN RECEPTOR FUNCTION | Bristol-Myers Squibb Company (US) | 2005-02-16 | — | — | EP | disclosed |
| WO-2003096980-A2 | BICYCLIC MODULATORS OF ANDROGEN RECEPTOR FUNCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-11-27 | — | — | WO | disclosed |
| US-6288036-B1 | ANTIINFLAMMATORY, ANTIASTHMATIC, ANTIALLERGEN, AND ANALGESIC AGENTS; ARGININE-CONTAINING NONA- OR DECAPEPTIDES | SCIOS INC. | 2001-09-11 | — | — | US | disclosed |
| EP-0618809-B1 | BRADYKININ TYPE PEPTIDES | SCIOS NOVA INC (US) | 1998-08-19 | — | — | EP | disclosed |
| EP-0618809-A1 | BRADYKININ TYPE PEPTIDES | SCIOS NOVA INC. (US) | 1994-10-12 | — | — | EP | disclosed |
| EP-0618809-A4 | BRADYKININ TYPE PEPTIDES. | SCIOS NOVA INC (US) | 1994-07-28 | — | — | EP | disclosed |
| WO-1992018155-A1 | BRADYKININ TYPE PEPTIDES | NOVA TECHNOLOGY LIMITED PARTNERSHIP (US) | 1992-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230339969-A1 | SUBSTITUTED MACROCYCLIC COMPOUNDS AND RELATED METHODS OF TREATMENT | HCRTR2, HCRTR1, CNR2 | SPHK1 280/4885SLC1A2 281/4885AGL 4327/4885 |
| US-11873291-B2 | Quinoline cGAS antagonist compounds | CGAS, GLS2, GLS | SPHK1 3192/4885SLC1A2 1445/4885AGL 2003/4885 |
| US-20210155636-A1 | Substituted Macrocyclic Compounds and Related Methods of Treatment | HCRTR2, HCRTR1, CNR2 | SPHK1 280/4885SLC1A2 281/4885AGL 4327/4885 |
| US-11542276-B2 | Substituted macrocyclic compounds and related methods of treatment | HCRTR2, HCRTR1, CNR2 | SPHK1 280/4885SLC1A2 281/4885AGL 4327/4885 |
| US-20220194958-A1 | Substituted Macrocyclic Compounds and Related Methods of Treatment | HCRTR2, HCRTR1, CNR2 | SPHK1 280/4885SLC1A2 281/4885AGL 4327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.